Over 8 Chinese Oligonucleotide Therapeutics Companies Secure Funding in 2025, Marking a 113% YoY Increase

It is worth mentioning that this is already theRound TwoFinancing. In May this year, AusperBio had just completed a US$50 million B+ round of financing. Completing two large rounds of financing in less than half a year indicates that the capital market is optimistic about its ASO therapy developed for liver diseases.

The case of AusperBio is not an isolated one. In fact, since the beginning of this year, several small nucleic acid enterprises have received substantial financial support, while others are actively preparing for IPOs. The entire small nucleic acid sector is attracting unprecedented attention and demonstrating a new and positive development trend.

According to incomplete statistics, from the beginning of 2025 to date, in ChinaAt least 8Small Nucleic Acid Companies Secure Financing, Total Funding Amount DisclosedApproximately RMB 2.445 billion(Source: Public information disclosed by the company)。

According to industry-related data, in 2024, a total of 13 small nucleic acid companies received financing, with an annual total financing amount of approximately 1.3 billion yuan. The total financing amount from Q1 to Q3 this year compared to the same period last year...(Approximately 1.15 billion yuan in the first three quarters of 2024)Increased by approximately 113%, achieving a doubling of growth.。

▲ Small Nucleic Acid Enterprises Securing Financing in 2025

Overall, this year's small nucleic acid sector financing presents"Full Rounds Coverage + Concentrated Large-Scale Financing"characteristics, and enterprises have different focuses on technical paths and pipeline layouts. Financing rounds cover all stages from seed round to Series E, showing not only the entire process from seed round to Series E but also indicating that some companies have entered a relatively mature later stage of development.

In addition, this year's financing also presented the following several significant characteristics:

In terms of financing amounts, the logic behind capital deployment at different stages is clear. It includes both early-stage seed round innovation cultivation and later-stage large-scale financing that recognizes maturity, with funding amounts generally higher from Series B onwards.

Among the companies that have disclosed the amount, except for Weicheng Pharmaceuticals which is at the seed round, the other six includeDaru Biotech, Jingyin Pharma, Carelink Pharmaceuticals, AusperBio, Ribo Biotech, and Haichang Biotech have all raised over 100 million yuan in funding this year.Among them, HiChuang Bio completed a C-round financing in August, which was as high asNearly 500 million yuan, and is one of the highest disclosed financing events this year.

Notably, several companies completed consecutive financings within a year. For instance, AusperBio secured its Series B+ and Series B2 rounds in May and September respectively, reflecting a continued boost in investor confidence.

This also indicates that as some leading companies advance their R&D pipelines and continuously validate clinical data, their demand for capital increases. Meanwhile, investors are willing to offer larger-scale support to companies with mature technology platforms and leading pipeline progress.

From the perspective of technical pathways, corporate layouts exhibit a trend of diversification. Small interfering RNA（siRNA) and antisense oligonucleotides(ASO) OperationAs the two mainstream technology platforms for small nucleic acid drugs, both have enterprises dedicated to in-depth development.

Moreover, almost all companies emphasized next-generation delivery technologies, especiallyExtrahepatic Delivery Technologydevelopment. For example, RiboBio has not only built the liver-targeting delivery platform RiboGalSTAR^TMTechnical Platform and Tumor-Targeted RiboOncoSTAR^TMTechnical platform, also built a non-liver targeted RiboPepSTAR^TMTechnology platform, throughPeptide Conjugation Enables Targeting of Kidney, Central Nervous System, and Other Tissues, demonstrating significant efficacy and safety across multiple disease models.

Breaking through the limitations of liver targeting and applying small nucleic acid drugs to a broader range of disease areas such as the central nervous system, ophthalmology, and oncology will be the key competitive point and value for the industry in the future.

From the pipeline layout of these enterprises that have received financing, the application fields of small nucleic acid drugs are continuously expanding, and the market ceiling is constantly being pushed higher.

Cardiometabolic diseases, chronic hepatitis BThis has become a popular field, closely related to the significant unmet clinical needs for such diseases and the liver being a natural target organ for small nucleic acid drugs.Weight Loss TrackSimilarly receiving significant attention, companies like Daring Bio have listed it as one of their development directions.

This diversified layout reflects the broad application prospects of the small nucleic acid technology platform, as well as the company's approach to seeking differentiated competition.

The financing boom in the small nucleic acid field in 2025 is an inevitable result of the technical accumulation and preliminary clinical value validation over the past few years, as well as the continued optimism of the capital market towards this field.

In the future, the development prospects of small nucleic acid drugs are broad. With the delivery(especially extrahepatic delivery)With the continuous iteration and breakthrough of technologies, the application scope of small nucleic acids will continue to expand, and their safety and efficacy will further improve. However, opportunities and challenges coexist. High R&D barriers, intensifying competition, and the ultimate commercialization test all require continued efforts from the entire industry.

It is foreseeable that the golden age of small nucleic acid drugs is accelerating, and the financing boom in 2025 is just the beginning. Continuous capital investment will accelerate the R&D and commercialization process of high-quality companies, driving the entire industry towards a more mature direction and promoting the widespread clinical adoption of small nucleic acid drugs to benefit more patients.

Shanghai Zhaowei Technology

Shanghai Zhaowei Technology Development Co., Ltd. has been deeply engaged in the nucleic acid field since its establishment in 1998. The company has established mRNA...A CDMO and small nucleic acid drug CDMO full industry chain platform, with a production base for small nucleic acid drugs at a ton-scale or above, providing services to customers.Providing development and production services from preclinical to commercialization stages, our independently developed enzymatic synthesis process technology has achieved public availability globally for the first time.Industrial production at the jin-level scale.

The company also has a phosphoramidite product line with an annual capacity of 58 tons, as well as raw material capacity supporting over 10.5 billion doses of mRNA vaccines.The company has established long-term cooperative relationships with biotechnology and pharmaceutical companies around the world, providing services for numerous nucleic acids in clinical stages and those already commercialized.Pipeline supplies raw materials.

For more information about Zhaowei Technology and its products and services, please visit the official website www.hongene.com and follow our WeChat Official Account "Shanghai Zhaowei Hongene".」。

Editorial Director | Xuan Xiao

Proofread by | Xuan Xiao

References:

1.Official Press Releases from Various Companies

2.https://mp.weixin.qq.com/s/fmLpqNNSaiUOon7klZTm0g

Statement:This article aims to convey industry development information and explore the cutting-edge progress in biomedicine. The content of the article represents the author's viewpoint, and does not represent the position of Eureka Biomedical, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal Moments, but unauthorized media or institutions are prohibited from reprinting it to other platforms in any form. If you need to reprint, please leave a message below the article to obtain authorization.

Cover image source: internet. If there is any copyright infringement, please contact us for removal.

DianDian "Share”、“Like" and "In Sight"，Give me a little recharge~